ArticleJournal of medical imaging and radiation oncology2025
Salvage Radiation Therapy for Localised Prostate Cancer Recurrence Following High-Intensity Focused Ultrasound (HIFU) Failure.
Article in Journal of medical imaging and radiation oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionProstate cancer is a prevalent malignancy with rising incidence rates globally. High-intensity focused ultrasound (HIFU) is a promising, minimally invasive treatment for localised prostate cancer. However, recurrence following HIFU, indicated by rising PSA levels or imaging-confirmed local recurrence, remains a concern. Salvage radiotherapy is a potential treatment for recurrent prostate cancer post-HIFU, but evidence on its efficacy and safety is limited.
methodThis retrospective study evaluated eight patients with localised prostate cancer who underwent salvage radiotherapy following HIFU failure. Salvage treatment consisted of external beam radiation therapy (EBRT), delivered either as conventional fractionation (76 Gy in 38 daily fractions) or stereotactic ablative radiotherapy (36.25-40 Gy in five alternate-day fractions). Outcomes assessed included prostate-specific antigen (PSA) response, biochemical progression-free survival (bPFS), overall survival (OS) and treatment-related toxicity profiles.
resultsAll eight patients experienced a significant decline in PSA levels, with no biochemical failures observed during a median follow-up of 72.4 months. The 5-year biochemical failure-free survival and overall survival rates were 100%. Among the eight patients, 6 (75%) had Grade 2 or lower genitourinary toxicity, and 5 (62.5%) had Grade 2 or lower gastrointestinal toxicity, with no Grade 3 or higher adverse events. DISCUSSION: Salvage EBRT after HIFU failure provides durable disease control with manageable side effects. Further research with larger cohorts is needed to refine treatment strategies for recurrent prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.